Home » Topics » BioWorld Science

BioWorld Science
RSS

Curadev Pharma targets ACSS2 for antitumor agents

April 25, 2018

Boehringer Ingelheim and Topas Therapeutics enter research agreement

April 25, 2018

First patient enrolled in phase III trial of topical ocular reproxalap

April 25, 2018

Results on sodium oxybate presented in pediatric patients with narcolepsy type 1

April 25, 2018

Third Rock Ventures launches Cedilla Therapeutics

April 25, 2018

Completion of phase I study of tozuleristide in pediatric brain tumor surgery

April 25, 2018

Nektar, Takeda to evaluate NKTR-214 in combination with TAK-659

April 25, 2018

Initiation of phase Ib trial of CMP-001 plus atezolizumab in anti-PD-1/PD-L1 resistant NSCLC

April 25, 2018

Procalcitonin predicts malignant cerebral edema after massive cerebral infarction

April 25, 2018

U.S. Navy describes novel anti-CD20 antibodies

April 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...